Skip to main content

Site notifications

Notice for lumacaftor/ivacaftor (Vertex Pharmaceuticals Australia Pty Ltd)

Active ingredients
lumacaftor/ivacaftor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Granules and tablets in fixed dose combinations
Indication
For the treatment of Cystic fibrosis
Therapeutic area
Respiratory

Help us improve the Therapeutic Goods Administration site